Novartis AG (NVS)
95.12
+0.76
(+0.81%)
USD |
NYSE |
Apr 22, 16:00
100.00
+4.88
(+5.13%)
Pre-Market: 07:14
Novartis Cash from Operations (TTM): 14.46B for Dec. 31, 2023
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 14.46B |
September 30, 2023 | 16.02B |
June 30, 2023 | 15.36B |
March 31, 2023 | 15.54B |
December 31, 2022 | 14.24B |
September 30, 2022 | 14.01B |
June 30, 2022 | 14.21B |
March 31, 2022 | 14.59B |
December 31, 2021 | 15.07B |
September 30, 2021 | 15.19B |
June 30, 2021 | 13.42B |
March 31, 2021 | 13.25B |
December 31, 2020 | 13.65B |
September 30, 2020 | 13.18B |
June 30, 2020 | 14.59B |
March 31, 2020 | 13.74B |
December 31, 2019 | 13.62B |
September 30, 2019 | 13.85B |
June 30, 2019 | 13.34B |
March 31, 2019 | 14.17B |
December 31, 2018 | 14.27B |
September 30, 2018 | 13.91B |
June 30, 2018 | 13.45B |
March 31, 2018 | 13.09B |
December 31, 2017 | 12.62B |
Date | Value |
---|---|
September 30, 2017 | 12.80B |
June 30, 2017 | 12.45B |
March 31, 2017 | 11.98B |
December 31, 2016 | 11.48B |
September 30, 2016 | 12.04B |
June 30, 2016 | 11.94B |
March 31, 2016 | 11.74B |
December 31, 2015 | 11.90B |
September 30, 2015 | 12.94B |
June 30, 2015 | 13.83B |
March 31, 2015 | 14.26B |
December 31, 2014 | 13.90B |
September 30, 2014 | 13.14B |
June 30, 2014 | 13.51B |
March 31, 2014 | 12.69B |
December 31, 2013 | 13.17B |
September 30, 2013 | 13.35B |
June 30, 2013 | 13.04B |
March 31, 2013 | 13.51B |
December 31, 2012 | 14.19B |
September 30, 2012 | 14.29B |
June 30, 2012 | 14.46B |
March 31, 2012 | 14.92B |
December 31, 2011 | 14.31B |
September 30, 2011 | 14.16B |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
13.18B
Minimum
Sep 2020
16.02B
Maximum
Sep 2023
14.28B
Average
14.21B
Median
Jun 2022
Cash from Operations (TTM) Benchmarks
Sandoz Group AG | -- |
Roche Holding AG | 18.04B |
Amgen Inc | 8.471B |
Incyte Corp | 496.49M |
MorphoSys AG | -- |